Topic: non-small cell lung cancer
The data show early signs of efficacy, with one-third of the heavily pretreated lung cancer patients enrolled in the trial having partial responses.
Thermo Fisher found that its blood tests could monitor the changing genetics of lung tumors and illustrate developments in drug resistance over time.
A retrospective study of Resolution’s blood test and Guardant360 found that it was able to detect a greater number of actionable mutations in NSCLC.
Xcovery has hired a CEO and CMO with Big Pharma experience to lead its efforts to challenge Pfizer, Roche and others for a lung cancer market.
A new assay that combines Illumina's ultradeep sequencing with Grail's machine-learning algorithm could detect multiple targetable cancer mutations.
Compugen is “streamlining” its R&D operations to pare down costs and ensure it can afford the phase 1 study of its lead asset, an anti-PVRIG antibody.
Taiho will grant an exclusive worldwide license—excluding Japan—to Cullinan in exchange for an upfront fee, milestones and royalties.
Nearly a year after its former chief Eliot Forster stepped down, Immunocore has a new full-time CEO in Medimmune’s president Bahija Jallal.
Pfizer’s Xalkori is hammered by new competition in the ALK-positive lung cancer space, and that’s where Lorbrena comes in.
AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.